Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fulcrum Therapeutics, Inc.FULC · Entity 5969 | Director | June 30, 2026 | July 02, 2026 |
| Keenova Therapeutics plcNONE · Entity 28960 | Director | July 15, 2026 | July 18, 2026 |
| Prelude Therapeutics IncPRLD · Entity 5561 | Director | June 09, 2026 | June 10, 2026 |
| TScan Therapeutics, Inc.TCRX · Entity 7255 | Director | May 20, 2026 | May 22, 2026 |
| Tectonic Therapeutic, Inc.AVRO · Entity 5328 | Chief Financial Officer | October 08, 2018 | October 10, 2018 |
| US Ecology, Inc.ECOL · Entity 127674 | Director | May 02, 2022 | May 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fulcrum Therapeutics, Inc.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.66 · Expires 2036-06-29 | Direct | 32,000 |
Reported balance
After 2026-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 32,000 · Balance 32,000 F1: This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
Keenova Therapeutics plc
Report date July 15, 2026 · Filed July 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 31,406 |
Reported balance
After 2026-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 4,406 · Balance 31,406 F1: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU. F2: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU.
F2: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders.
Prelude Therapeutics Inc
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2036-06-08 | Direct | 38,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 38,000 · Balance 38,000 F1: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.
TScan Therapeutics, Inc.
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.99 · Expires 2036-05-20 | Direct | 67,000 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 67,000 · Balance 67,000 F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.
Tectonic Therapeutic, Inc.
Report date October 08, 2018 · Filed October 10, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2018-10-08 transaction · row 1
1 source rowRow 1 · 2018-10-08 · Exercise / conversion · Acquired 10,000 · Balance 10,000 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.91 · Expires 2027-07-19 | Direct | 148,318 |
Reported balance
After 2018-10-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-10-08 · Exercise / conversion · Disposed 10,000 · Balance 148,318 F1: 25% of the shares vested on August 28, 2018, and the remaining 75% vest in equal monthly installments thereafter over a three-year period. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares vested on August 28, 2018, and the remaining 75% vest in equal monthly installments thereafter over a three-year period.
US Ecology, Inc.
Report date May 02, 2022 · Filed May 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-05-02 transaction · row 1
1 source rowRow 1 · 2022-05-02 · Disposition to issuer · Disposed 10,070 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), entered into on February 8, 2022, by and among the Issuer, Republic Services, Inc. ("Parent") and Bronco Acquisition Corp. (filed as Exhibit 2.1 to the Form 8-K filed with the Securities and Exchange Commission on February 10, 2022). At the effective time of the merger, each Issuer share of common stock issued and outstanding immediately prior to the effective time of the merger was converted into the right to receive $48.00 per share in cash without interest ("Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectRetirement Account | 0 |
Reported balance
After 2022-05-02 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2022-05-02 · Disposition to issuer · Disposed 3,430 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), entered into on February 8, 2022, by and among the Issuer, Republic Services, Inc. ("Parent") and Bronco Acquisition Corp. (filed as Exhibit 2.1 to the Form 8-K filed with the Securities and Exchange Commission on February 10, 2022). At the effective time of the merger, each Issuer share of common stock issued and outstanding immediately prior to the effective time of the merger was converted into the right to receive $48.00 per share in cash without interest ("Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), entered into on February 8, 2022, by and among the Issuer, Republic Services, Inc. ("Parent") and Bronco Acquisition Corp. (filed as Exhibit 2.1 to the Form 8-K filed with the Securities and Exchange Commission on February 10, 2022). At the effective time of the merger, each Issuer share of common stock issued and outstanding immediately prior to the effective time of the merger was converted into the right to receive $48.00 per share in cash without interest ("Merger Consideration").
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Pandion Therapeutics, Inc.
Report date April 01, 2021 · Filed April 01, 2021
Section 16 reporting ended · disclosed 2021-04-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.96 · Expires 2030-12-01 | Direct | 0 |
Reported balance
After 2021-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-01 · Disposition to issuer · Disposed 27,994 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the "Company"), Merck Sharp & Dohme Corp. ("Merck") and Panama Merger Sub, Inc. ("Merger Sub"), Merger Sub commenced a tender offer (the "Offer") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the "Offer Price"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the "Merger") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price. F3: Disposed of pursuant to the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2: All options were vested and exercisable as of immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the "Company"), Merck Sharp & Dohme Corp. ("Merck") and Panama Merger Sub, Inc. ("Merger Sub"), Merger Sub commenced a tender offer (the "Offer") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the "Offer Price"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the "Merger") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price.
F2: All options were vested and exercisable as of immediately prior to the Effective Time.
F3: Disposed of pursuant to the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option.
US Ecology Holdings, Inc.
Report date November 01, 2019 · Filed November 01, 2019
Section 16 reporting ended · disclosed 2019-11-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-11-01 transaction · row 1
1 source rowRow 1 · 2019-11-01 · Disposition to issuer · Disposed 5,170 · Balance 0 F1: Disposed pursuant to that certain Agreement and Plan of Merger, dated as of June 23, 2019, by and among US Ecology Holdings, Inc. (f/k/a US Ecology, Inc.) ("Parent"), NRC Group Holdings Corp., US Ecology, Inc. (f/k/a US Ecology Parent, Inc.) ("Holdco"), ECOL Merger Sub, Inc. ("ECOL Merger Sub") and Rooster Merger Sub, Inc., in a merger transaction in which ECOL Merger Sub merged with and into Parent, and each issued and outstanding share of Parent's common stock was converted into the right to receive, and became exchangeable for, one share of common stock, par value $0.01 of Holdco. |
| Common StockSEC Table I · non-derivative | IndirectRetirement Account | 0 |
Reported balance
After 2019-11-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-11-01 · Disposition to issuer · Disposed 2,330 · Balance 0 F1: Disposed pursuant to that certain Agreement and Plan of Merger, dated as of June 23, 2019, by and among US Ecology Holdings, Inc. (f/k/a US Ecology, Inc.) ("Parent"), NRC Group Holdings Corp., US Ecology, Inc. (f/k/a US Ecology Parent, Inc.) ("Holdco"), ECOL Merger Sub, Inc. ("ECOL Merger Sub") and Rooster Merger Sub, Inc., in a merger transaction in which ECOL Merger Sub merged with and into Parent, and each issued and outstanding share of Parent's common stock was converted into the right to receive, and became exchangeable for, one share of common stock, par value $0.01 of Holdco. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed pursuant to that certain Agreement and Plan of Merger, dated as of June 23, 2019, by and among US Ecology Holdings, Inc. (f/k/a US Ecology, Inc.) ("Parent"), NRC Group Holdings Corp., US Ecology, Inc. (f/k/a US Ecology Parent, Inc.) ("Holdco"), ECOL Merger Sub, Inc. ("ECOL Merger Sub") and Rooster Merger Sub, Inc., in a merger transaction in which ECOL Merger Sub merged with and into Parent, and each issued and outstanding share of Parent's common stock was converted into the right to receive, and became exchangeable for, one share of common stock, par value $0.01 of Holdco.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 12, 2016 Filed Sep 14, 2016 09:55 UTC | US Ecology Holdings, Inc. ECOL · Entity 154125 | PurchaseCommon Stock | 1,330 | $44.33 | $58,953.85 |
DisclosureSEC source: 0001437749-16-038672 · rdgdoc.xml · nonDerivative · entry 2 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,070 F1 · shares: Shares were purchased by the reporting person's IRA. Read SEC document |
| September 12, 2016 Filed Sep 14, 2016 09:55 UTC | US Ecology Holdings, Inc. ECOL · Entity 154125 | SaleCommon Stock | 1,330 | $44.36 | $58,998.93 |
DisclosureSEC source: 0001437749-16-038672 · rdgdoc.xml · nonDerivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,070 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.